clinical outcomes – Page 2

Clinical experience of primary subcutaneous mycoses in Shanghai: a retrospective analysis

mycolabadmin

Researchers in Shanghai studied 33 patients with deep skin fungal infections that had become increasingly common in the area. They identified 13 different fungal species causing these infections, most commonly Candida parapsilosis, Trichophyton rubrum, and Sporothrix schenckii. Patients were treated with antifungal medications tailored to the specific fungus and its drug sensitivity, with most patients recovering completely, though some experienced relapses, emphasizing the importance of long-term follow-up care.

Frequency, Interval, and Patient Factors Associated With Recurrence of Disseminated Cutaneous Coccidioidomycosis

mycolabadmin

This study looked at how often a serious fungal skin infection called coccidioidomycosis comes back after treatment. Researchers found that about 25% of patients experienced at least one recurrence after stopping antifungal medications, with the average time before it returned being 14 months. Some patients had multiple recurrences, and most of the time the infection returned to the same location on the body.

Recalcitrant dermatophytosis due to Trichophyton indotineae: A case series from Sarawak, Malaysia

mycolabadmin

Three patients in Malaysia had persistent skin fungal infections caused by Trichophyton indotineae that did not respond to standard antifungal treatments. Genetic testing revealed these fungal strains carried a specific mutation making them resistant to terbinafine, the typical first-line treatment. While azole-based antifungals showed variable effectiveness depending on the specific drug and dose used, one patient achieved complete cure with voriconazole therapy. The study highlights the growing problem of drug-resistant fungal infections and the importance of targeted treatment based on laboratory testing.

Evaluation of Clinical, Microbiological Profiles and Management Patterns with Outcomes of Patients with Fungal Isolates in An Intensive Care Unit of A Tertiary Care Center: A Prospective Observational Study

mycolabadmin

This study examined fungal infections in patients staying in intensive care units at a hospital. Researchers found that diabetes was the most common risk factor, and a fungus called Candida tropicalis was the most frequently isolated organism from urine samples. Many of the fungal strains were resistant to fluconazole, a common antifungal medication, suggesting doctors need to choose different treatments based on which drugs the fungi are resistant to.

Trichosporon species bloodstream infections in a tertiary care hospital in the western region of Saudi Arabia: A 7-year retrospective chart review from 2016 to 2022

mycolabadmin

This study examined a rare but dangerous fungal infection called Trichosporonosis that affects the bloodstream in hospitalized patients. Researchers found that this infection kills about 60% of patients despite treatment with antifungal medications. The infection is often caused by a fungus called Trichosporon asahii and typically occurs in patients with weakened immune systems who are already hospitalized and using catheters.

Persistent Candidemia: Predictors and Outcomes in a Multicenter Matched Analysis

mycolabadmin

This study examined cases where fungal infections caused by Candida persisted in the bloodstream even after starting antifungal treatment. Researchers compared 46 patients with persistent infections to 92 control patients without persistent infections across three major medical centers. Patients with persistent candidemia were younger, more likely to be female, had more health complications, and sadly had much higher death rates (54% vs 31%) within 90 days. The findings suggest that certain patient characteristics and fungal species types may help identify those at higher risk of persistent infections.

Clinical Outcomes of Micafungin for Invasive Fungal Infections in the Obese and Nonobese

mycolabadmin

This study examined whether obese patients treated with the antifungal drug micafungin for serious fungal infections had different outcomes compared to non-obese patients. Researchers reviewed 378 patient cases and found that both groups had similar success rates of about 50%, suggesting that the standard dose of micafungin works equally well in obese and non-obese patients. These findings suggest that doctors do not need to prescribe higher doses of micafungin specifically for obese patients, though more research is needed to fully understand how obesity affects antifungal treatment.

Clinical, Laboratory, and Biomarker Predictors of 90-Day Mortality in Non-HIV, Non-Transplant Pneumocystis Pneumonia

mycolabadmin

This study examined pneumocystis pneumonia in immunocompromised patients who do not have HIV or transplants. Researchers found that older patients with other health conditions were at higher risk of death within 90 days. High levels of fungal markers and low immune cell counts were better predictors of poor outcomes than traditional inflammation markers, suggesting doctors should focus on early identification and personalized treatment approaches.

Research Keyword: clinical outcomes